United Kingdom-based AstraZeneca has completed sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma, it was reported yesterday.
The deal is valued at USD350m. Under the terms of the deal, Covis will also make conditional sales-related payments for the three drugs of up to USD21m to AstraZeneca over four years starting from 2019.
The divested rights by AstraZeneca to Covis Pharma includes markets outside the US and the US royalties for the three over-the-counter drugs. Omnaris is an inhaled anti-inflammatory maintenance therapy that is administered through a metered-dose inhaler to help control persistent asthma. The other two products were developed for the treatment of nasal symptoms resulting from seasonal allergic and allergic/non-allergic perennial rhinitis.
The deal was first announced in November this year and does not include the transfer of any AstraZeneca employees or facilities to Covis.
Gilead Sciences reveals data from the phase three Stellar-four study of selonsertib
Biopharma Veterans Kevin Young and Una Ryan Join Cortexyme Board of Directors
Artios Pharma elects Rajesh Chopra PhD as non-executive director
First Subject Dosed with Monoclonal Antibody Encoded by mRNA in a Clinical Trial
Can-Fite Receives Notice of Allowance from US Patent and Trademark Office for Osteoarthritis Drug
KalVista Pharmaceuticals Names Pereira to Board of Directors
Innovus Pharma Launches OTC Hemorrhoid Xyralid Suppositories in Canada
Novus Therapeutics Advances OP0201 Development Programme Across Several Clinical Trials